Opthea Limited (AU:OPT) has released an update.
Opthea Limited has successfully completed patient enrollment for two Phase 3 trials, ShORe and COAST, in their wet AMD program, and anticipates topline data in early and mid-2025 respectively. The company has also strengthened its financial position by raising A$227.3 million through a Placement and Entitlement Offer, bolstering its commitment to developing therapies for retinal diseases like wet AMD and DME. Additionally, new leadership appointees bring extensive experience in medical affairs and biopharmaceuticals, promising to drive the company’s strategic growth.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.
